Exfoliative dermatitis - Dermatitis Exfoliative
☆ I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Red (burning) Skin Syndrome ― Erythema me te unahi ki te tinana katoa nga tohu matua o Dermatitis Exfoliative (Exfoliative dermatitis).
relevance score : -100.0%
ReferencesKo te Erythroderma he mate kiri onge engari he kino. Ahakoa kaore i te mohiotia te take tika, ka puta mai i te drug reaction, i te cancer o raro ranei. Ko tetahi mate pukupuku noa e hono ana ki te dermatitis exfoliative ko te cutaneous T‑cell lymphoma, kare pea e whakaatu tohu mo nga marama, mo nga tau ranei i muri i te tiimata o te mate kiri. I te nuinga o te waa, ka hiahiatia te biopsy mo te aromatawai tuatahi me te maimoatanga. Ko nga turoro e mau ana i te mate na roto i te tarukino he pai te tirohanga mo te wa roa, ahakoa ko nga keehi kaore he take marama, ka hoki mai ano, ka tukuna. Ko te tohu mo nga keehi e hono ana ki te cancer ka whakawhirinaki ki te ahua o te ahunga whakamua o te cancer.
Erythroderma is a rare but serious skin condition. While the exact cause is often unknown, it can be triggered by a drug reaction or an underlying cancer. One common cancer linked to exfoliative dermatitis is cutaneous T-cell lymphoma, which might not show symptoms for months or even years after the skin condition starts. Usually, hospitalization is needed for initial assessment and treatment. Patients with drug-induced disease generally have a good long-term outlook, though cases without a clear cause tend to have a recurring and remitting course. The prognosis for cases linked to cancer typically depends on how the cancer progresses.
Erythroderma is a rare but serious skin condition. While the exact cause is often unknown, it can be triggered by a drug reaction or an underlying cancer. One common cancer linked to exfoliative dermatitis is cutaneous T-cell lymphoma, which might not show symptoms for months or even years after the skin condition starts. Usually, hospitalization is needed for initial assessment and treatment. Patients with drug-induced disease generally have a good long-term outlook, though cases without a clear cause tend to have a recurring and remitting course. The prognosis for cases linked to cancer typically depends on how the cancer progresses.
I te nuinga o te wa ka kitea te whero (redness) me te pahekeheke (scaling) e hipoki ana i te 90 % o te tinana. Ko tēnei ahuatanga he tohu kitea o ngā momo take hauora kei raro pērā i te psoriasis, eczema, he ururape rānei ki ētahi rongoā.
It characteristically demonstrates diffuse erythema and scaling of greater than 90% of the body surface area. It is a reaction pattern and cutaneous manifestation of a myriad of underlying ailments, including psoriasis and eczema, or a reaction to the consumption of certain drugs.
It characteristically demonstrates diffuse erythema and scaling of greater than 90% of the body surface area. It is a reaction pattern and cutaneous manifestation of a myriad of underlying ailments, including psoriasis and eczema, or a reaction to the consumption of certain drugs.
Ko te take tino nui o te erythroderma ko te whakaparahako o te mate kiri o raro, pērā i te psoriasis, te contact dermatitis, te seborrheic dermatitis, te lichen planus, te pityriasis rubra pilaris, te whakautu rongoā (drug reaction), pērā i te whakamahi i ngā rūkō (steroids). He iti ake te paheketanga tuatahi, ka kitea i te nuinga o ngā wā o te lymphoma T‑cell kiri (cutaneous T‑cell lymphoma). Nā te mea he mea nui ki te wehewehe i te lymphoma T‑cell kiri (cutaneous T‑cell lymphoma), ka mahia he whakawhiwhi (biopsy).